Schizophrenia and Schizoaffective Disorder Research Studies

* A Family Study of Schizophrenia and Related Conditions - The University of Pittsburgh is conducting a study into the genetic causes of schizophrenia. Volunteers with a diagnosis of Schizophrenia or Schizoaffective disorder and their family members are needed. [list][*]No changes in treatment.[*]All information is strictly confidential.[*]No travel required, an interviewer will come to participant's home.[*]All participants are paid for their contributions.[/list:u] For information, please call TOLL FREE: 1-877-363-5895. Research sponsored by NIMH through a grant to Dr. V.L. Nimgaonkar, M.D., Ph.D., Professor of Psychiatry and Human Genetics at the University of Pittsburgh.

* Manhattan Psychiatric Center: A Bridge to Recovery - Does someone you know have schizophrenia? We are recruiting patients for a research study of an approved medication for a new use to see if this will enhance general and cognitive functioning in individuals with schizophrenia. To qualify for participation, individuals must be: between 18 and 55 years of age; in good general physical health; diagnosed with schizophrenia; stable on Abilify, Risperdal, Seroquel, or Zyprexa for the last 8 weeks AND have no unstable medical illness and no problems with drugs or alcohol. Participation in this study is voluntary. We will offer compensation for some travel expenses. For more information about this study, please call (646) 672-6179, Dr. B.J. Parker, Manhattan Psychiatric Center Psychopharmacology Research Unit. Note: The study will be conducted at the Outpatient Clinic of the Manhattan Psychiatric Research Center at 125th Street, NY, NY 10035.

* Creighton University Department of Psychiatry - Have you been diagnosed with schizophrenia and recently needed hospitalization, outpatient crisis management, or short-term treatment in an emergency room? If so, you might qualify to participate in a research study comparing the effectiveness and safety between Zyprexa Olanzapine and Seroquel Quetiapine. To be eligible, you must also: be between the ages of 19 and 75; be stable for at least 30 days; have been taking 10 - 20 mg/day (Zyprexa) Olanzapine; be able to come to the Creighton Psychiatry Clinic 13 times over a 26 week period. We offer: $25 per visit for time and travel; physical examination, laboratory work-up, eye-exam and study medication at no cost to you. If you are interested in participating in this research study, please call Kim at 345-8828 X22. Creighton University Department of Psychiatry, 3528 Dodge Street, Omaha, NE 68131.

* The Center for Cognitive Medicine at the University of Illinois at Chicago, Department of Psychiatry is looking for individuals to participate in a study investigating emotional and cognitive functioning in schizophrenia and major depression. You may be eligible to participate in the study if you meet these conditions: [list][*]Age between 18-55 years[*]Diagnosis of schizophrenia or major depression, with symptoms currently stabilized or in remission[*]No history of neurological illness, seizures, head injury, or longstanding learning difficulties that might interfere with cognitive functioning[*]No current substance abuse or past history of substance dependence[/list:u] Participation involves: [list][*]a detailed interview to assess your psychological functioning (about 1 hour)[*]psychological tests that measure your verbal and spatial abilities, memory capacities, attentional skills, and responses to emotional stimuli (about 3 ½ to 4 hours)[/list:u] Testing and interviewing can be completed at our offices at the UIC Medical Center, or at alternate locations if travel to UIC is problematic for participants. Participants are compensated for their time, and also for travel expenses over $25. For more information, call Ms. WooJin Song (312) 413-1867 or Ellen Herbener, Ph.D. (312) 413-4612 or e-mail: wsong@psych.uic.edu.

*Help Us Solve the Schizophrenia Puzzle: The National Institute of Mental Health (NIMH) has joined forces with university medical schools across the country including Harvard, UCLA, UCSD, Mount Sinai, Univ. of Pennsylvania, Univ. of Washington, and the Univ. of Colorado. Through this collaborative research project we hope to learn more about the genetic basis of schizophrenia. Understanding the genetic components of schizophrenia is crucial to finding out about the risk factors, and heritability of this illness. It may also help us to create more effective treatments, and hopefully, someday, find a cure.

What if my family does not live near any of the schools listed? In some cases we will be able to accommodate family members who do not live near any of the testing sites. Each situation is different, but we hope to include as many families as possible. We will not ask you to change your medication in any way. The study lasts about 2-half days. Each participant will be paid for time spent participating in the study. For additional questions about this study go to www.schizophreniaresearch.net

*Early Detection of Schizophrenia: A new Mental Illness Prevention Center is being established which will include several research studies. One research study will take place at both New York University School of Medicine and the Nathan S. Kline Institute for Psychiatric Research. Adolescents and young adults in the age range of 12-30 will be evaluated with several measures of how they function. If you or one of your family members are between the ages of 12-30, have a close relative who has been diagnosed with schizophrenia or you are having trouble functioning at home, school or work, you may be eligible for participation in these research evaluations. There is no cost to you for participating. If a psychiatrist feels you are in need of treatment, youwill be referred to an appropriate facility for your needs. This referral treatment will be at your own expense. Please contact us at familystudy2@aol.com.

* Family Volunteers Needed for Research Study on the Genetics of Schizophrenia: We are looking for families who have one or more members with a diagnosis of schizophrenia. If you or someone in your close family has schizophrenia, you may be eligible for participation in a research study to find genes that influence brain functioning. The study involves having a brain MRI scan, psychological testing and an interview. At least 2 or more members of your family between the ages of 18-55 are needed for the study. All information collected will remain confidential. All expenses involved in your participation will be paid. Please contact us at familystudy2@aol.com for more information.

* Schizophrenia Research Study: Men and women between 18 and 65 years old are needed to participate ini a clinical research study of a marketed drug in the investigational treatment of schizophrenia. If you or someone you know has schizophrenia, and current medications are not working, you may be interested in a clinical research trial. Volunteers must be diagnosed with schizophrenia and must be able to consent to participation in a clinical study before beginning any study-related activities. All office visits, medical evaluations, and study medications related to this study will be provided at no cost to patients. To learn more, visit these websites: www.SchizophreniaTrial.com, www.VeritasMedicine.com, www.Caregiver.com, or www.Schizophrenia.com, or call this toll free number 888-818-7377.

* SCHIZOPHRENIA MEDICATION COMPLIANCE STUDY: You are invited to participate in a research study regarding your attitudes about and use of medications prescribed to address symptoms of schizophrenia. You have been selected to participate in this study because you are viewing this message on this bulletin board or chat room. To be eligible to participate in this research study, you must be at least 18 years old, have a current diagnosis of schizophrenia, be able to effectively communicate in English using email and currently be residing in the United States of America. This message has been posted to the general list of bulletin board or chat room members, and there will be no record kept of who received, opened, or responded to this invitation other than data you choose to provide. Your prompt response is important.

The experience of participation is a time consuming one, and will require a total of two hours of your time over three sittings at your computer. Specifically, this program is an attempt to understand how people make decisions about taking medication as prescribed or not. Your decision whether to participate in the program is entirely private and voluntary. There will be no benefit to you if you decide to participate, and there will be no risk or penalty to you if you decide not to participate. There may be some risks if you decide to participate, these risks include emotional discomfort due to being made to consider potentially upsetting thoughts or experiences, and anxiety about revealing personal information about your medication taking behavior. Participation in this research study will provide no immediate benefits to you. It may, over time, result in improvements in treatment for people with diagnoses similar to yours. No one other than the researcher will know your email address and no one will ask you for your name or other identifying information. All email addresses and other identifying information will be destroyed when this study is complete, and no record will be maintained.

If you would like to participate in this study, you must have an internet connection, an email account, and reply indicating your interest to: jxs53@po.cwru.edu. This study is being conducted at The Mandel School of Applied Social Sciences at Case Western Reserve University in Cleveland, Ohio. The researchers conducting this study are Kathleen Farkas, PhD (you may contact Dr. Farkas by email at kjf@po.cwru.edu or by calling 216-368-2276) and John Sinclair (you may contact John Sinclair via email at jxs53@cwru.edu or by calling 216-321-2339). You may also contact Dr. Farkas, John Sinclair or the Mandel School by calling toll free: (800) 863-6772. The mailing address for both Dr. Farkas and John Sinclair is: Mandel School of Applied Social Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7164

If you would like to talk to someone other than the researcher(s) about; (1) concerns regarding this study, (2) research participant rights, (3) research-related injuries, or (4) other human subjects issues, please contact Case Western Reserve University’s Institutional Review Board at (216) 368-6925 or write: Case Western Reserve University; Institutional Review Board; 10900 Euclid Ave.; Cleveland, OH 44106-7230. If you wish to participate in this research study, please open an email addressed to jxs53@po.cwru.edu, send the message "I want to participate in your study", be certain your return email address appears and is accurate, and click the send button.

* Schizophrenia, schizoaffective disorder or bipolar disorder in Ashkenazi Jewish families: Study focuses on a population with less genetic variation than the general population because of a limited number of ancestors and a history of marriage within the faith. Any individual with one of the diagnoses may participate. Participation of parents and any affected siblings is highly desirable. Ann Pulver 888/289-4095 (toll-free) or e-mail: familystudy@jhmi.edu

* Outpatient study involving individuals with schizophrenia and at least one sibling with or without schizophrenia. In addition to an interview and blood draw for genetics studies, participants have neuropsychological testing, brain imaging, a neurological exam, and recordings of brain waves and eye movements. NIMH can assist with lodging and travel expenses, and families receive compensation for the extensive testing. Visit http://cbdb.nimh.nih.gov/ for further information. Contact: Mary Weirich, 1-888-674-6464 (toll-free) or email: weirichm@intra.nimh.nih.gov

* The Clinical Brain Disorders Branch, specializing in the field of schizophrenia, is conducting a six-month inpatient research study at the National Institutes of Mental Health, a pre-eminent facility, in Bethesda, Maryland. The program is free of charge, involving extensive diagnostic evaluations, medication-free studies, neuroimaging, psychological and neurological testing. Compassionate, competent staff also offers art therapy, educational groups, and occupational/recreational therapy. Participants must be between the ages of 18 and 65, be diagnosed with schizophrenia or schizoaffective disorder, and be free of significant medical/neurological illnesses and active substance abuse. For more information, please call: Victor Blythe at 301-594-0874 or call toll-free at 1-888-674-NIMH (6464) or e-mail: victor.blythe@nih.gov; or Web site: http://cbdb.nimh.nih.gov/inpatient

* NIMH Genetic Study of Schizophrenia Protocol # 95-M-0150 - The Schizophrenia Research Program at the National Institute of Mental Health located at on the campus of the National Institutes of Health in Bethesda, Maryland, is seeking healthy adults diagnosed with schizophrenia or schizoaffective disorder (depressed type) to participate in a two-day outpatient study. Travel and lodging assistance is provided and a stipend is also given to participants. This study seeks to identify the genetic and environmental factors that increase the risk of developing schizophrenia. The procedures include confidential interviews and a blood draw, a neurological exam and neuropsychological testing, neuroimaging, and recordings of eye movements and brain waves. Siblings are also invited to participate in these procedures and parents are invited to give a sample of blood if possible. For more details, call the toll-free schizophrenia studies referral line at 1-888-674-6464 (TTY: 866-411-1010) at NIH, Department of Health & Human Services.

* NIMH Seeks Volunteers for Six-Month Schizophrenia Study - The Schizophrenia Research Program at the National Institute of Mental Health specializes in the field of schizophrenia and is conducting a six-month inpatient research study of the neurobiological causes of schizophrenia at the National Institutes of Health in Bethesda, Maryland. The program involves extensive psychological, psychiatric, neurological, and medical evaluations, and neuroimaging. Study participation involves a period of time without medications. Throughout their stay in the research program, participants receive expert, personalized care, and are encouraged to participate in the clinical milieu that provides educational programs, recreational and occupational therapy, and art and music therapies. Participants must be between the ages of 18 and 55, be diagnosed with schizophrenia or schizoaffective disorder, and be free of significant medical/neurological illnesses and active substance abuse. There is no charge to participate. For more details, call the schizophrenia research referral line at 1-888-674-6464.

*Treatment Studies for Early Onset Schizophrenic Spectrum Disorders - McLean Hospital in Belmont, MA is conducting two experimental drug treatment studies of children and adolescents who suffer from psychosis. The studies will examine the short and long term effects of different medications.Benefits of participation in these studies: a comprehensive psychiatric and medical evaluation conducted by staff at McLean Hospital, a full year of antipsychotic medication with close monitoring, and psychoeducation and support by a team of skilled clinicians who have extensive experience working with these children.We are looking for males and females ages 8-19, who have at least one active psychotic symptom (peculiar fantasies, delusions, hallucinations, cognitive disorganization) or are diagnosed with a schizophrenia spectrum disorder and are in good health.

Study #1 – TEOSS (Treatment of Early Onset Schizophrenic Spectrum Disorders) - This study is funded through the National Institute of Health and compares three medications, risperidone (Risperdal), olanzapine (Zyprexa), and molindone (Moban). Over a full year children are assessed for clinical benefit, cognitive improvement, and overall health. Subjects must be willing to be tapered off of any antidepressants or mood stabilizers prior to starting treatment. If interested, please contact Emily Gerstein at 617-855-3694, egerstein@mclean.harvard.edu.

Study #2 – An Open Trial of Ziprasidone in Youth – This study will assess the effectiveness of one medication, ziprasidone (Geodon). Every subject will receive the ziprasidone treatment. For this study, subjects do not need to be weaned off antidepressants or mood stabilizers. If interested, please contact Emily Gerstein at 617-855-3694, egerstein@mclean.harvard.edu.

Reimbursement – For both studies, subjects will be reimbursed up to $310 for their time over the course of the year.

*Families Affected by Schizophrenia: Harvard Medical School and the Consortium on the Genetics of Schizophrenia (COGS) are conducting a research study on the effect of genes on information-processing in patients with schizophrenia and their relatives. Our immediate goal is to understand better the genetic basis of schizophrenia, with the long-term vision of creating better treatment options for patients with the illness. To participate, families must have one member diagnosed with schizophrenia, both biological parents, and at least one biological sibling willing to participate. Participants will each be compensated $10 per hour of participation, along with transportation costs. Study procedures include an interview, blood draw, drug screening, and testing of attention, memory, EEG’s, and eye movements. Information will be kept confidential. For more information, please contact Erica Lee at 617-998-5011or e-mail: Erica_Lee@hms.harvard.edu .

*Participants Needed for Genetic Studies of Schizophrenia. A major research group at the Mount Sinai School of Medicine is conducting two comprehensive studies that focus on Schizophrenia. There is a tendency for schizophrenia to run in families, however most family members never develop the illness. Mount Sinai’s studies aim to identify genetic factors that may predispose some family members to develop schizophrenia. Finding genes for schizophrenia will help researchers understand more about the biological causes of the illness. As a result, we will likely be able to develop more effective treatments for future generations. If you or one of your family members has schizophrenia, you may be eligible to participate in one of our studies. Participation will include one blood sample, interviews about psychiatric and family history, and may also include a visit to our lab in Manhattan. Scheduling for interviews and blood draw are made to best suit the family member, and may be conducted either in the home or at the hospital site. Each family member will receive financial compensation for his or her contribution. If you are interested in participating and/or would like more information about the studies, please contact: Robert Fieo, Clinical Research Coordinator, Phone: 212-369-5214, Email: familystudies@mssm.edu -- Family Studies Research Center, 57-59 96th St. Suite 1D, New York, NY 10029

* If you are at least 18-years-old and have been diagnosed with Schizophrenia you may be eligible to participate in a nation-wide research study to determine the genetics of Schizophrenia. You can be in any state in the United States and contact Sentelle or Lisa by toll-free telephone at 1-877-259-4355, or by email at seubanks@uci.edu or llovil@uci.edu -- If you participate, you will be interviewed at a convenient time for approximately 2-3 hours by toll-free telephone, at your home or on the University of California, Irvine campus. You will be asked to give approximately 6 tablespoons of blood and will receive $100 for your participation.

* A University of Iowa Health Care Investigation is searching for the genes that cause schizophrenia. By identifying these genes, experts hope to develop better treatments for this important brain disease. The study seeks individuals ages 18 and older who have schizophrenia. Volunteers give a blood sample and undergo a clinical interview during one visit to UI Hospitals and Clinics or a convenient site statewide. Compensation is available. For more information, contact Jessica Deadrick, study coordinator in psychiatry, at (319) 353-3339.

*Adolescent Schizophrenia Study: Participants are needed for a new adolescent schizophrenia research study of an atypical anti-psychotic investigational medication known as Olanzapine. Teenagers must be between ages 13-17 and be diagnosed with schizophrenia or displaying the symptoms of schizophrenia. To learn more about participating in this research study, please visit www.teenmentalhealth.net or call toll free 1-866-874-2518.

*Volunteer Families Needed for a Research Study: For several years now, studies have been conducted at the UCLA Neuropsychiatric Institute by principal investigator, Robert Asarnow, PhD., on how children who are diagnosed with schizophrenia and related disorders pay attention and process information. We are now beginning a research study in an effort to learn more about the role of genetics among children with schizophrenia and their family members. This current study is funded by the National Institute of Mental Health. We are asking families with a history of childhood-onset schizophrenia to take part in the study. The study involves a detailed psychiatric and neuropsychological assessment of your child and each family member who volunteers to take part, as well as the collection of detailed psychological information on all members of your family tree. All participants are asked to provide a blood sample and a swab of cells from the inside of the cheek. As a thank you, we will compensate families for their time and effort. We will also cover expenses for parking and meals. If you are interested in finding out more specific information about the study and to find out whether your family might be eligible to participate, please call the project's toll free number, (866) 739-2039. We hope to hear from you. It is through the support of families such as yours that we are able to learn more about serious childhood psychiatric illnesses such as schizophrenia.

*Dr. Erica Duncan at the Atlanta VA Medical Center and the Department of Psychiatry and Behavioral Sciences of the Emory University School of Medicine is conducting a research study about sensory information. We are looking at sensorimotor gating (the ability to filter out sensory information, or information we hear). We are doing this study with people diagnosed with schizophrenia or a schizophrenia-related problem, with family members of participating subjects with schizophrenia, and with people who have no current/past psychiatric, drug, or alcohol problems. This study does not involve medication. The ideal participant will be either someone who is: [list][*]Age 20-80 years old [*]Right or Left Handed [*]Diagnosed with schizophrenia or a related diagnosis [*]Not drug or alcohol dependent OR [*]someone with no current/past psychiatric drug alcohol problems[/list:u] Participation will take 5-6 hours and will involve: [list][*]Brief prescreening interview and hearing screening [*]Screening interviews about medical & psychiatric history [*]Several ratings and interviews about symptoms [*]Neuropsychological Testing, Computer and Acoustic Startle Testing [*]Urine Drug Screen and Blood Draw for DNA analysis [*]Eligible subjects will be compensated for their participation in the study.[/list:u] For more information, please contact Barbara Lewison or Megan Keyes, Research Coordinators: (404) 321-6111, ext. 7155 or 6967

* Treatment study for Children and Adolescents with Bipolar Disorder or Schizophrenia Spectrum Disorders: This study is an experimental drug study for children and adolescents ages 10-17 with Bipolar Disorder or schizophrenia spectrum disorders. This study will test the safety and efficacy of a research medication called ziprasidone (Geodon) in children and adolescents with these diagnoses. The study lasts up to 27 weeks.

BENEFITS OF PARTICIPATION [list][*]Up to 27 weeks of antipsychotic medication [*]A study-related psychiatric and medical evaluation conducted by staff at McLean Hospital in Belmont, MA [*]Reimbursement up to $275 for travel and time[/list:u] Inclusion Criteria [list][*]10-17 years old, male or female [*]Diagnosed with Bipolar Disorder or a schizophrenia spectrum disorder [*]Patients taking antidepressants or mood stabilizers must be willing to be weaned off them prior to starting study treatment, and stay off them for the first three weeks of treatment [*]Patients must also be weaned off any other antipsychotics before entering the study, and stay off them for the duration of the study[*]Patients must not be pregnant or abusing substances[/list:u] If you are interested in learning more about this study, please contact: Emily Gerstein, Study Coordinator, Tel: 617-855-3694

* Researchers at Harvard Medical School are studying a new way of treating schizophrenia. Current medications only treat symptoms of schizophrenia, not the cause. The treatment we are studying may result in a more lasting improvement of symptoms by normalizing a biological process that is thought to be irregular in this disorder. This treatment involves taking an FDA-approved medication, in addition to the subject’s current medication. We are recruiting subjects who are: [list][*]Schizophrenic [*]18 – 25 years old [*]taking risperidone (Risperdal)[/list:u] Compensation up to $250 will be provided. For more information, please call Andrea at 617-998-5010.

*Clinical Trial Opportunity for those 18 years or older with DSM IV Diagnosis of Schizophrenia: Gabriel Pharma is a leading biotechnology company whose research studies are funded by The National Institutes of Health and whose mission is to improve the understanding and treatment of mental illness. Under the leadership of Dr. David Pickar, MD (Capt. USPH-Ret.), former Chief of The Experimental Therapeutics Branch, NIMH, Gabriel Pharma is a leader of clinical neuroscience research in the biotechnology community.

Clinical Research Study: Clinical Assessment of Schizophrenia Patients and DNA Collection for Genetic Screening related to Predicting Drug Response: Dr. David Pickar,MD Principal Investigator

Study Description: Schizophrenia is a "complex" genetic disorder that is it is a disease in which genetic factors affect risk, clinical appearance, including severity, outcome and response to medication. In order to understand complex inherited disorders, researchers have increasingly turned toward genetic association studies. The principal objective of this protocol is to establish genetic predictors of outcome in schizophrenic patients. Careful clinical assessment of schizophrenic patients will be performed and blood collection for DNA extraction for each subject will be performed. This protocol involves a clinical interview and a venous blood sample. There is no drug administration or other treatment involved in this protocol.

Compensation: Each subject will receive $75 upon completion of the clinical assessment and blooddraw (an appointment not to exceed three hours).

Contact Person: Catherine Pickar, Project Coordinator, Gabriel Pharma, LLC, 6500 Seven Locks Road, Suite 220, Cabin John, MD 20818. Phone 301-263-1315

* SCHIZOPHRENIA MEDICATION COMPLIANCE STUDY: You are invited to participate in a research study regarding your attitudes about and use of medications prescribed to address symptoms of schizophrenia.

You have been selected to participate in this study because you are viewing this message on this bulletin board or chat room. To be eligible to participate in this research study, you must be at least 18 years old, have a current diagnosis of schizophrenia, be able to effectively communicate in English using email and currently be residing in the United States of America.

This message has been posted to the general list of bulletin board or chat room members, and there will be no record kept of who received, opened, or responded to this invitation other than data you choose to provide. Your prompt response is important.

The experience of participation is a time consuming one, and will require a total of two hours of your time over three sittings at your computer. Specifically, this program is an attempt to understand how people make decisions about taking medication as prescribed or not.

Your decision whether to participate in the program is entirely private and voluntary. There will be no benefit to you if you decide to participate, and there will be no risk or penalty to you if you decide not to participate.

There may be some risks if you decide to participate, these risks include emotional discomfort due to being made to consider potentially upsetting thoughts or experiences, and anxiety about revealing personal information about your medication taking behavior.

Participation in this research study will provide no immediate benefits to you. It may, over time, result in improvements in treatment for people with diagnoses similar to yours.

No one other than the researcher will know your email address and no one will ask you for your name or other identifying information. All email addresses and other identifying information will be destroyed when this study is complete, and no record will be maintained.

If you would like to participate in this study, you must have an internet connection, an email account, and reply indicating your interest to: jxs53@po.cwru.edu.

This study is being conducted at The Mandel School of Applied Social Sciences at Case Western Reserve University in Cleveland, Ohio.

The researchers conducting this study are Kathleen Farkas, PhD (you may contact Dr. Farkas by email at kjf@po.cwru.edu or by calling 216-368-2276) and John Sinclair (you may contact John Sinclair via email at jxs53@cwru.edu or by calling 216-321-2339). You may also contact Dr. Farkas, John Sinclair or the Mandel School by calling toll free: (800) 863-6772.

The mailing address for both Dr. Farkas and John Sinclair is: Mandel School of Applied Social Sciences, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106-7164

If you would like to talk to someone other than the researcher(s) about; (1) concerns regarding this study, (2) research participant rights, (3) research-related injuries, or (4) other human subjects issues, please contact Case Western Reserve University’s Institutional Review Board at (216) 368-6925 or write: Case Western Reserve University; Institutional Review Board; 10900 Euclid Ave.; Cleveland, OH 44106-7230.

If you wish to participate in this research study, please open an email addressed to jxs53@po.cwru.edu, send the message "I want to participate in your study", be certain your return email address appears and is accurate, and click the send button.